Tom Marrs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tom Marrs has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Gideon Lack
Department of Women and Children's Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine King's College London London UK
4 shared publications - Carsten Flohr
St John's Institute of Dermatology King's College London and Guy's & St Thomas' NHS Foundation Trust London UK
3 shared publications Gideon Lack
Paediatric Allergy, Department of Women and Children's Health King's College London Strand UK
3 shared publicationsKirsty Logan
Paediatric Allergy, Department of Women and Children's Health, King’s College London , London
3 shared publications- Michael Richard Perkin
Population Health Research Institute St. George's University of London London UK
3 shared publications Joanna Craven
Department of Paediatric Allergy, Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London. Strand, WC2R 2LS, UK
2 shared publications
Latest Publications
- Open Access
- 16 January 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 923-934
Associations between early-life exposures and the infant skin microbiome
Background: Factors influencing the early-life skin microbiome and the association with atopic dermatitis (AD) are relatively unexplored. Objectives: To evaluate associations with the infant skin microbiome during the first year of life. Methods: Three-month-old infants from the Enquiring About Tolerance (EAT) birth cohort were examined for AD at enrolment and at 1 and 3 years of age. Parent-completed questionnaires, transepidermal water loss (TEWL) and FLG mutation status were evaluated. Bacterial swabs were collected from the elbow crease and volar forearm from 148 infants at 3 months and 1 year of age, and the microbiome composition was characterized using 16S rRNA gene sequencing (V3–V4 region). Results: Shannon diversity was significantly higher at the forearm compared with the elbow. Staphylococcus, Acinetobacter and Streptococcus were the most abundant genera across time and body site. Microbiome community composition was primarily associated with body site and age (P ≤ 0.001 for both). Other significant associations were found with ethnicity (P = 0.009), FLG status (P ≤ 0.001), urban vs. rural residence (P = 0.005), older siblings (P = 0.04) and bath product use at 3 months (P = 0.01) but not with pets (P = 0.16), systemic antibiotics (P = 0.27) or bathing frequency (P = 0.11). The microbiome was associated with elevated TEWL (P = 0.004 at 3 months and P ≤ 0.001 at 1 year) and with concurrent AD (P = 0.03 at 3 months, P ≤ 0.001 at 1 year). Streptococcus parasanguinis was significantly less abundant in the nonlesional skin of infants with AD at 3 months. Conclusions: In addition to age and body site, the infant skin microbiome is associated with heritable factors, the home environment, hygiene practices and with the presence of AD. An author video to accompany this article is available online.
- 16 January 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (5) , 923-934
Open AccessAssociations between early-life exposures and the infant skin microbiome
Background: Factors influencing the early-life skin microbiome and the association with atopic dermatitis (AD) are relatively unexplored. Objectives: To evaluate associations with the infant skin microbiome during the first year of life. Methods: Three-month-old infants from the Enquiring About Tolerance (EAT) birth cohort were examined for AD at enrolment and at 1 and 3 years of age. Parent-completed questionnaires, transepidermal water loss (TEWL) and FLG mutation status were evaluated. Bacterial swabs were collected from the elbow crease and volar forearm from 148 infants at 3 months and 1 year of age, and the microbiome composition was characterized using 16S rRNA gene sequencing (V3–V4 region). Results: Shannon diversity was significantly higher at the forearm compared with the elbow. Staphylococcus, Acinetobacter and Streptococcus were the most abundant genera across time and body site. Microbiome community composition was primarily associated with body site and age (P ≤ 0.001 for both). Other significant associations were found with ethnicity (P = 0.009), FLG status (P ≤ 0.001), urban vs. rural residence (P = 0.005), older siblings (P = 0.04) and bath product use at 3 months (P = 0.01) but not with pets (P = 0.16), systemic antibiotics (P = 0.27) or bathing frequency (P = 0.11). The microbiome was associated with elevated TEWL (P = 0.004 at 3 months and P ≤ 0.001 at 1 year) and with concurrent AD (P = 0.03 at 3 months, P ≤ 0.001 at 1 year). Streptococcus parasanguinis was significantly less abundant in the nonlesional skin of infants with AD at 3 months. Conclusions: In addition to age and body site, the infant skin microbiome is associated with heritable factors, the home environment, hygiene practices and with the presence of AD. An author video to accompany this article is available online.
- Open Access
- 26 June 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (7) , 459-469
BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study
Background: Palforzia® enables the safe and effective desensitisation of children with peanut allergy. The treatment pathway requires multiple visits for dose escalation, up‐dosing, monitoring of patients taking maintenance therapy and conversion onto daily real‐world peanut consumption. The demand for peanut immunotherapy outstrips current National Health Service (NHS) capacity and requires services to develop a national consensus on how best to offer Palforzia® in a safe and equitable manner. We undertook a Delphi consensus exercise to determine guidance statements for the implementation of Palforzia®‐based immunotherapy in the NHS.Methods: We undertook focus groups with children and young people who had received peanut immunotherapy to assess what was important for them and their carers. Common themes from patients formed the basis of creating draft statements. A panel of 18 multi‐disciplinary professionals engaged in two rounds of anonymised voting to adapt the statements and score their importance. A final consensus workshop consolidated any variation in comments and scores to develop the final guidance statements.Results: The panel achieved consensus on 91% (29/32) of guidance statements, demonstrating strong consensus around pragmatic principles for assuring the integrity of consent, safety and conversion from Palforzia® to real‐world peanut products. The greatest amount of feedback was generated from three broad issues; (i) whether eligibility assessment should include compulsory peanut challenges and whether these should be designed to assess the threshold at which patients react to peanut, (ii) the governance processes to best ensure that patients' interests are prioritised and (iii) how to safely transition young people to other services, or discharge them, while they are taking daily peanut.Conclusions: This consensus highlights the urgent need for the NHS to increase capacity for undertaking diagnostic food challenges as well as developing Palforzia® immunotherapy pathways. The voting panel agreed that families of peanut allergic children should be made aware of immunotherapy, that eligibility assessment should include how co‐morbid conditions are managed and that services should monitor for adverse effects. The finalised statements are now published online for clinical practice in the UK. These guidance statements will be adapted in the coming years as more evidence is published and as the international experience of peanut immunotherapy evolves.
- 26 June 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (7) , 459-469
Open AccessBSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study
Background: Palforzia® enables the safe and effective desensitisation of children with peanut allergy. The treatment pathway requires multiple visits for dose escalation, up‐dosing, monitoring of patients taking maintenance therapy and conversion onto daily real‐world peanut consumption. The demand for peanut immunotherapy outstrips current National Health Service (NHS) capacity and requires services to develop a national consensus on how best to offer Palforzia® in a safe and equitable manner. We undertook a Delphi consensus exercise to determine guidance statements for the implementation of Palforzia®‐based immunotherapy in the NHS.Methods: We undertook focus groups with children and young people who had received peanut immunotherapy to assess what was important for them and their carers. Common themes from patients formed the basis of creating draft statements. A panel of 18 multi‐disciplinary professionals engaged in two rounds of anonymised voting to adapt the statements and score their importance. A final consensus workshop consolidated any variation in comments and scores to develop the final guidance statements.Results: The panel achieved consensus on 91% (29/32) of guidance statements, demonstrating strong consensus around pragmatic principles for assuring the integrity of consent, safety and conversion from Palforzia® to real‐world peanut products. The greatest amount of feedback was generated from three broad issues; (i) whether eligibility assessment should include compulsory peanut challenges and whether these should be designed to assess the threshold at which patients react to peanut, (ii) the governance processes to best ensure that patients' interests are prioritised and (iii) how to safely transition young people to other services, or discharge them, while they are taking daily peanut.Conclusions: This consensus highlights the urgent need for the NHS to increase capacity for undertaking diagnostic food challenges as well as developing Palforzia® immunotherapy pathways. The voting panel agreed that families of peanut allergic children should be made aware of immunotherapy, that eligibility assessment should include how co‐morbid conditions are managed and that services should monitor for adverse effects. The finalised statements are now published online for clinical practice in the UK. These guidance statements will be adapted in the coming years as more evidence is published and as the international experience of peanut immunotherapy evolves.
- Open Access
- 29 February 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (3) , 169-184
Optimising the management of peanut allergy by targeting immune plasticity
Randomised controlled trials investigating the efficacy of oral tolerance induction to peanut have enabled detailed comparison of their clinical and immunological success. They have demonstrated that the regular consumption of peanut for at least 2 years by babies who are not allergic enables protection from developing peanut allergy. The LEAP study intervention tested the impact of regular peanut consumption for 4 years and demonstrated a sustained protection against the development of peanut allergy even after 12 months of peanut avoidance from 5 to 6 years of age. The PreventADALL trial introduced multiple allergens into babies' diets from early infancy and reduced the prevalence of food allergy at 3 years, especially by protecting against peanut allergy. Immunological studies from the LEAP cohort demonstrated that regular peanut consumption was associated with a prompt induction of peanut‐specific IgG4 and reduced manufacture of peanut and Ara h 2‐specific IgE. Even after stopping peanut consumption for 5 years, there continued to be a significant fall in peanut‐specific Ara h 2 IgE in the consumption group from 5 to 6 years of age (p < .01). Children who developed peanut allergy by 5 years started to develop increasing sensitisation to linear sequential peanut epitopes from 2.5 years of age, suggesting that putative disease‐modifying interventions should commence before 3 years. Data comparing clinical outcomes between children undergoing peanut immunotherapy from infancy suggest that younger children can consume higher portions of peanut without reaction on challenge whilst taking immunotherapy, have fewer side effects and are more likely to enjoy remission of PA. Peanut oral immunotherapy modulates T‐cell populations in order to bring about hypo‐responsiveness of allergy effector cells. Studies are now needed to characterise and compare different states of immunological tolerance. This will accelerate the design of interventions which can promote primary, secondary and tertiary levels of PA prevention across a range of age groups.
- 29 February 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (3) , 169-184
Open AccessOptimising the management of peanut allergy by targeting immune plasticity
Randomised controlled trials investigating the efficacy of oral tolerance induction to peanut have enabled detailed comparison of their clinical and immunological success. They have demonstrated that the regular consumption of peanut for at least 2 years by babies who are not allergic enables protection from developing peanut allergy. The LEAP study intervention tested the impact of regular peanut consumption for 4 years and demonstrated a sustained protection against the development of peanut allergy even after 12 months of peanut avoidance from 5 to 6 years of age. The PreventADALL trial introduced multiple allergens into babies' diets from early infancy and reduced the prevalence of food allergy at 3 years, especially by protecting against peanut allergy. Immunological studies from the LEAP cohort demonstrated that regular peanut consumption was associated with a prompt induction of peanut‐specific IgG4 and reduced manufacture of peanut and Ara h 2‐specific IgE. Even after stopping peanut consumption for 5 years, there continued to be a significant fall in peanut‐specific Ara h 2 IgE in the consumption group from 5 to 6 years of age (p < .01). Children who developed peanut allergy by 5 years started to develop increasing sensitisation to linear sequential peanut epitopes from 2.5 years of age, suggesting that putative disease‐modifying interventions should commence before 3 years. Data comparing clinical outcomes between children undergoing peanut immunotherapy from infancy suggest that younger children can consume higher portions of peanut without reaction on challenge whilst taking immunotherapy, have fewer side effects and are more likely to enjoy remission of PA. Peanut oral immunotherapy modulates T‐cell populations in order to bring about hypo‐responsiveness of allergy effector cells. Studies are now needed to characterise and compare different states of immunological tolerance. This will accelerate the design of interventions which can promote primary, secondary and tertiary levels of PA prevention across a range of age groups.
- 17 February 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (2) , e13739
Basophil CD63 assay to peanut allergens accurately diagnoses peanut allergy in patient with negative skin prick test and very low specific IgE
- 17 February 2022
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 33 (2) , e13739
Basophil CD63 assay to peanut allergens accurately diagnoses peanut allergy in patient with negative skin prick test and very low specific IgE
- 7 December 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 82-93
Frequency of guideline‐defined cow's milk allergy symptoms in infants: Secondary analysis of EAT trial data
Background: Non‐IgE‐mediated Cow's Milk Allergy (CMA) has a prevalence of less than 1% in children. Guidelines developed to help non‐specialists diagnose CMA may lead to misattribution of normal symptoms and contribute to overdiagnosis of CMA. We sought to establish the frequency of symptoms during infancy associated with non‐IgE‐mediated CMA, using the international Milk Allergy in Primary Care (iMAP) guideline as representative of CMA guidelines more generally.Method: Secondary analysis of the Enquiring About Tolerance (EAT) randomized controlled trial (ISRCTN 14254740; 1303 exclusively breastfed 3‐month‐old healthy infants). Key outcomes were ≥2 iMAP symptoms associated with ‘mild‐moderate’ and ‘severe’ non‐IgE‐mediated CMA.Results: Whilst breastfeeding and parental atopy rates were higher than the general population, participants were otherwise similar to the population of England and Wales. Two or more non‐IgE CMA symptoms were reported by 25% families for mild‐moderate and 1.4% for severe symptoms each month between ages 3 and 12 months, peaking at 38% with ≥2 mild‐moderate and 4.3% ≥2 severe symptoms at three months, when participants were not directly consuming cow's milk. 74% of participants reported ≥2 mild‐moderate symptoms and 9% ≥2 severe symptoms in at least one month during this period. At six months there was no evidence of difference in the proportion of children with ≥2 symptoms between those consuming (29.5% mild‐moderate, 1.8% severe) and not consuming cow's milk (35.3% mild‐moderate, 2.2% severe). Mean monthly reporting of ≥2 symptoms was also no different between those with (15.8% mild‐moderate, 1.1% severe) or without eczema at baseline (16.7% mild‐moderate, 1.3% severe).Conclusions: Guideline‐defined symptoms of non‐IgE‐mediated CMA are very common in infants. Guidelines may promote milk allergy overdiagnosis by labelling normal infant symptoms as possible milk allergy.
- 7 December 2021
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (1) , 82-93
Frequency of guideline‐defined cow's milk allergy symptoms in infants: Secondary analysis of EAT trial data
Background: Non‐IgE‐mediated Cow's Milk Allergy (CMA) has a prevalence of less than 1% in children. Guidelines developed to help non‐specialists diagnose CMA may lead to misattribution of normal symptoms and contribute to overdiagnosis of CMA. We sought to establish the frequency of symptoms during infancy associated with non‐IgE‐mediated CMA, using the international Milk Allergy in Primary Care (iMAP) guideline as representative of CMA guidelines more generally.Method: Secondary analysis of the Enquiring About Tolerance (EAT) randomized controlled trial (ISRCTN 14254740; 1303 exclusively breastfed 3‐month‐old healthy infants). Key outcomes were ≥2 iMAP symptoms associated with ‘mild‐moderate’ and ‘severe’ non‐IgE‐mediated CMA.Results: Whilst breastfeeding and parental atopy rates were higher than the general population, participants were otherwise similar to the population of England and Wales. Two or more non‐IgE CMA symptoms were reported by 25% families for mild‐moderate and 1.4% for severe symptoms each month between ages 3 and 12 months, peaking at 38% with ≥2 mild‐moderate and 4.3% ≥2 severe symptoms at three months, when participants were not directly consuming cow's milk. 74% of participants reported ≥2 mild‐moderate symptoms and 9% ≥2 severe symptoms in at least one month during this period. At six months there was no evidence of difference in the proportion of children with ≥2 symptoms between those consuming (29.5% mild‐moderate, 1.8% severe) and not consuming cow's milk (35.3% mild‐moderate, 2.2% severe). Mean monthly reporting of ≥2 symptoms was also no different between those with (15.8% mild‐moderate, 1.1% severe) or without eczema at baseline (16.7% mild‐moderate, 1.3% severe).Conclusions: Guideline‐defined symptoms of non‐IgE‐mediated CMA are very common in infants. Guidelines may promote milk allergy overdiagnosis by labelling normal infant symptoms as possible milk allergy.
- Open Access
Pros and cons: Is faecal microbiota transplantation a safe and efficient treatment option for gut dysbiosis?
Faecal Microbiota Transplantation (FMT) is well established as an effective treatment for Clostridioides difficile infection (CDI), restoring gut microbiome diversity and function. The utility of FMT is currently being explored in relation to other immune‐mediated pathologies, such as allergic disease, inflammatory bowel diseases and autoimmune diseases. Clinical trials in these areas are ongoing, and the altered gut microbiota (dysbiosis) that is often observed in these pathologies provides a rationale for the application of FMT to restore the microbiome. However, there is controversy on the risk‐benefit ratio as it relates to the use of FMTs in pathologies other than CDI. In this Pro and Con article, we present the arguments for and against the use of FMT in immune‐mediated pathologies, such as allergic disease. We further identify research gaps and recommend how these may be addressed in future studies.
Open AccessPros and cons: Is faecal microbiota transplantation a safe and efficient treatment option for gut dysbiosis?
Faecal Microbiota Transplantation (FMT) is well established as an effective treatment for Clostridioides difficile infection (CDI), restoring gut microbiome diversity and function. The utility of FMT is currently being explored in relation to other immune‐mediated pathologies, such as allergic disease, inflammatory bowel diseases and autoimmune diseases. Clinical trials in these areas are ongoing, and the altered gut microbiota (dysbiosis) that is often observed in these pathologies provides a rationale for the application of FMT to restore the microbiome. However, there is controversy on the risk‐benefit ratio as it relates to the use of FMTs in pathologies other than CDI. In this Pro and Con article, we present the arguments for and against the use of FMT in immune‐mediated pathologies, such as allergic disease. We further identify research gaps and recommend how these may be addressed in future studies.
- 1 September 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (8) , 2820-2822
Bathing frequency is associated with skin barrier dysfunction and atopic dermatitis at three months of age
- 1 September 2020
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 8 (8) , 2820-2822
Bathing frequency is associated with skin barrier dysfunction and atopic dermatitis at three months of age
Dog ownership at three months of age is associated with protection against food allergy
Background: The prevention of food allergy is a key priority for reducing the burden of allergic disease. Environmental exposures modulate the risk of developing food allergy and some of this may be mediated by the infants’ developing microbiome. However, the role of potentially protective environmental exposures, such as pet ownership, is largely uninvestigated with respect to food allergy.Methods: We performed a secondary cohort analysis in the Enquiring About Tolerance (EAT) study, which enrolled 1303 three‐month infants onto a randomized trial to prevent food allergy. A survey elicited domestic animal ownership and participants were examined for atopic dermatitis (AD) at enrolment. Sensitization to foods and aeroallergens were elicited by skin and serum testing at 3, 12 and 36 months. Food allergy status was determined by double‐blind placebo‐controlled food challenges between 1 and 3 years.Results: Food allergy was diagnosed amongst 6.1% (68/1124) of participants with complete data. No significant relationships were demonstrated between food allergy and caesarean delivery, infections or antibiotic exposure in early life. After adjusting for familial atopic disease, maternal dog/cat sensitization and participant AD, living with dogs was associated with a 90% reduction in the odds of infants developing food allergy (adjusted odds ratio (aOR) 0.10 (confidence interval (CI) 0.01‐0.71), P = 0.02). None of the 49 infants living with at least two dogs developed food allergy, suggesting a dose‐response relationship (each dog owned aOR 0.12 (CI 0.02‐0.81), P = 0.03). No relationship was demonstrated between owning dogs or cats and the development of AD.Conclusion: Dog ownership in infancy may prevent food allergy.
Dog ownership at three months of age is associated with protection against food allergy
Background: The prevention of food allergy is a key priority for reducing the burden of allergic disease. Environmental exposures modulate the risk of developing food allergy and some of this may be mediated by the infants’ developing microbiome. However, the role of potentially protective environmental exposures, such as pet ownership, is largely uninvestigated with respect to food allergy.Methods: We performed a secondary cohort analysis in the Enquiring About Tolerance (EAT) study, which enrolled 1303 three‐month infants onto a randomized trial to prevent food allergy. A survey elicited domestic animal ownership and participants were examined for atopic dermatitis (AD) at enrolment. Sensitization to foods and aeroallergens were elicited by skin and serum testing at 3, 12 and 36 months. Food allergy status was determined by double‐blind placebo‐controlled food challenges between 1 and 3 years.Results: Food allergy was diagnosed amongst 6.1% (68/1124) of participants with complete data. No significant relationships were demonstrated between food allergy and caesarean delivery, infections or antibiotic exposure in early life. After adjusting for familial atopic disease, maternal dog/cat sensitization and participant AD, living with dogs was associated with a 90% reduction in the odds of infants developing food allergy (adjusted odds ratio (aOR) 0.10 (confidence interval (CI) 0.01‐0.71), P = 0.02). None of the 49 infants living with at least two dogs developed food allergy, suggesting a dose‐response relationship (each dog owned aOR 0.12 (CI 0.02‐0.81), P = 0.03). No relationship was demonstrated between owning dogs or cats and the development of AD.Conclusion: Dog ownership in infancy may prevent food allergy.
- 17 July 2015
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 15 (8) , 1-8
Oral Food Challenges: The Design must Reflect the Clinical Question
Oral food challenges are the gold-standard diagnostic investigation for diagnosing food allergy. They allow a subject to consume an age-appropriate portion of allergenic food under surveillance to assess whether a reproducible immune-mediated adverse response is demonstrated. The specific design of food challenge must closely reflect the anticipated management step being considered. In clinical practice, food challenges are most commonly used to investigate the subject’s status of allergy or tolerance to a food. However, other characteristics of food allergy are increasingly being investigated through recent studies. In particular, studies investigating food allergy prevention strategies, the impact of oral immunotherapy on subjects’ threshold for allergic reactions and also their potential acquisition of long-term tolerance each utilize differing designs of oral food challenges to investigate their specific hypothesis. We examine how oral food challenges may be designed to assess specific characteristics of the food allergic response.
- 17 July 2015
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 15 (8) , 1-8
Oral Food Challenges: The Design must Reflect the Clinical Question
Oral food challenges are the gold-standard diagnostic investigation for diagnosing food allergy. They allow a subject to consume an age-appropriate portion of allergenic food under surveillance to assess whether a reproducible immune-mediated adverse response is demonstrated. The specific design of food challenge must closely reflect the anticipated management step being considered. In clinical practice, food challenges are most commonly used to investigate the subject’s status of allergy or tolerance to a food. However, other characteristics of food allergy are increasingly being investigated through recent studies. In particular, studies investigating food allergy prevention strategies, the impact of oral immunotherapy on subjects’ threshold for allergic reactions and also their potential acquisition of long-term tolerance each utilize differing designs of oral food challenges to investigate their specific hypothesis. We examine how oral food challenges may be designed to assess specific characteristics of the food allergic response.